联合抑制表面CD51与γ-分泌酶介导的CD51剪切可提高实验性转移性肝细胞癌的治疗疗效
本研究利用多种肝细胞癌(HCC)细胞系、小鼠肝癌细胞系、三维侵袭实验、体内生物发光成像、骨膜蛋白敲除转基因小鼠及患者来源类器官和异种移植模型,发现CD51经γ-分泌酶跨膜剪切产生功能性胞内结构域(CD51-ICD),后者通过促进氧化磷酸化相关基因转录促进HCC侵袭和转移;癌相关成纤维细胞来源的骨膜蛋白是CD51剪切的主要驱动因素;在患者来源类器官和异种移植模型中,西仑吉肽联合γ-分泌酶抑制剂LY3039478取得显著治疗效果。
要点
- CD51可被γ-分泌酶跨膜剪切产生功能性胞内结构域CD51-ICD。
- CD51-ICD通过促进氧化磷酸化相关基因转录促进HCC侵袭和转移。
- 癌相关成纤维细胞来源的骨膜蛋白是CD51剪切的主要驱动因素。
核心结论
- 本研究揭示了CD51参与HCC进展的先前未知机制,并揭示了西仑吉肽治疗失败的潜在原因,为联合CD51靶向治疗的临床转化前景提供了证据。
研究设计与样本
- 研究使用多种肝细胞癌(HCC)细胞系和小鼠肝癌细胞系,采用三维侵袭实验和体内生物发光成像研究CD51在HCC进展中的作用。
- 研究使用骨膜蛋白敲除转基因小鼠揭示肿瘤微环境对CD51剪切的作用。
- 研究使用多种临床相关HCC模型,包括患者来源类器官和患者来源异种移植,评估西仑吉肽联合γ-分泌酶抑制剂LY3039478的治疗疗效。
主要发现
- CD51可经γ-分泌酶跨膜剪切产生功能性胞内结构域(CD51-ICD)。
- 剪切产生的CD51-ICD通过促进氧化磷酸化相关基因转录促进HCC侵袭和转移。
- 癌相关成纤维细胞来源的骨膜蛋白被确定为CD51剪切的主要驱动因素。
- 在患者来源类器官和异种移植模型中,西仑吉肽联合LY3039478取得显著治疗效果。
- CD51在细胞核中的定位与HCC患者预后显著相关。
临床怎么用
- 作者认为这些发现为在临床环境中重新评估西仑吉肽提供了理论基础,并强调在未来针对CD51的临床试验中识别更精确患者亚群的重要性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Integrin αv (ITGAV, CD51) is regarded as a key component in multiple stages of tumor progression. However, the clinical failure of cilengitide, a specific inhibitor targeting surface CD51, suggests the importance of yet-unknown mechanisms by which CD51 promotes tumor progression. METHODS: In this study, we used several hepatocellular carcinoma (HCC) cell lines and murine hepatoma cell lines. To investigate the role of CD51 on HCC progression, we used a 3D invasion assay and in vivo bioluminescence imaging. We used periostin-knockout transgenic mice to uncover the role of the tumor microenvironment on CD51 cleavage. Moreover, we used several clinically relevant HCC models, including patient-derived organoids and patient-derived xenografts, to evaluate the therapeutic efficacy of cilengitide in combination with the γ-secretase inhibitor LY3039478. RESULTS: We found that CD51 could undergo transmembrane cleavage by γ-secretase to produce a functional intracellular domain (CD51-ICD). The cleaved CD51-ICD facilitated HCC invasion and metastasis by promoting the transcription of oxidative phosphorylation-related genes. Furthermore, we identified cancer-associated fibroblast-derived periostin as the major driver of CD51 cleavage. Lastly, we showed that cilengitide-based therapy led to a dramatic therapeutic effect when supplemented with LY3039478 in both patient-derived organoid and xenograft models. CONCLUSIONS: In summary, we revealed previously unrecognized mechanisms by which CD51 is involved in HCC progression and uncovered the underlying cause of cilengitide treatment failure, as well as providing evidence supporting the translational prospects of combined CD51-targeted therapy in the clinic. IMPACT AND IMPLICATIONS: Integrin αv (CD51) is a widely recognized pro-tumoral molecule that plays a crucial role in various stages of tumor progression, making it a promising therapeutic target. However, despite early promising results, cilengitide, a specific antagonist of CD51, failed in a phase III clinical trial. This prompted further investigation into the underlying mechanisms of CD51's effects. This study reveals that the γ-secretase complex directly cleaves CD51 to produce an intracellular domain (CD51-ICD), which functions as a pro-tumoral transcriptional regulator and can bypass the inhibitory effects of cilengitide by entering the nucleus. Furthermore, the localization of CD51 in the nucleus is significantly associated with the prognosis of patients with HCC. These findings provide a theoretical basis for re-evaluating cilengitide in clinical settings and highlight the importance of identifying a more precise patient subpopulation for future clinical trials targeting CD51.
引用
- Cai J, Wang J, Jiang C, et al. Combined inhibition of surface CD51 and γ-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma. J Hepatol. 2023. PMID: 37604269. doi:10.1016/j.jhep.2023.08.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。